Chemocentryx, Inc.

Amgen Inc.

Other

Ju Yang

Penglie Zhang

Manmohan Reddy Leleti

Venkat Reddy Mali

Christopher W Lange

Rajinder Paul Singh

Jay Patrick Powers

Hiroko Tanaka

Viengkham Malathong

Yandong Li

Sreenivas Punna

Pingchen Fan

Dean R Dragoli

Rebecca M Lui

Junfa Fan

Jeffrey P McMahon

Chao Yu

Yibin Zeng

Xi Chen

Jaroslaw Kalisiak

Darren J McMurtrie

Antoni Krasinski

Trevor T Charvat

Kevin Lloyd Greenman

Howard S Roth

Daniel J Dairaghi

Matthew J Walters

Joanne Tan

Ryan J Scamp

Yu Wang

James J Campbell

Karen Ebsworth

Shijie Li

Jeffrey P McMAHON

Darren J McMURTRIE

Kwok Yau

Aubrie Harland

Daniel R Marshall

Jeffrey P MacMahon

Jarek Kalisiak

Jeffrey Mcmahon

Jay Powers

Hiroko Tankaka

Manmahon Reddy Leleti

Darren J Mcmurtrie

Chritopher Lange

Daniel Dairaghi

Yangdong Li

Jeffrey P Mcmahon

Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.

Azetidinyl-acetamides as CXCR7 inhibitors

Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, A, Z, Xand n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases

Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.

2-oxindole compounds

Compounds of formula (A) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:

Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors

The present disclosure is drawn to the combination therapy of a C-C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.

Combination therapy using C—C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors

Compounds are provided as inhibitors of CXCR2, having the structure:

Inhibitors of CXCR2

Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.

Substituted anilines as CCR(4) antagonists

Compounds represented by Formula (I) or (II): are provided herein, or a pharmaceutically acceptable salt, or a prodrug or bioisostere thereof; wherein R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, Y, Y′, and the subscripts m and n are as defined herein.

Indanes as PD-L1 inhibitors

Compounds are provided as chemokine inhibitors having the structure:

Modulators of chemokine receptors

Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (II):

Immunomodulator compounds

Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, R, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Indane-amines as PD-L1 antagonists

Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases

Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein Z, L, R, R, R, R, R, R, R, R, R, R, R, R, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include dministering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. In some embodiments, the CCR6 and/or CXCR2 antagonist has the formula:

Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2

Growing community of inventors

Palo Alto, CA, United States of America

Ju Yang